CTCAE RápidoAdverse event grades · CTCAE v6.0
  1. G1Adult: Subjective change in hearing in the absence of documented hearing loss; threshold shift of 15 - 25 dB averaged at 2 contiguous test frequencies in at least one ear (on a 1, 2, 4, 3, 6, and 8 kHz audiogram); Pediatric (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift >20 dB hearing loss (HL) (i.e., 25 dB HL or greater); sensorineural hearing loss (SNHL) above 4 kHz (i.e., 6 or 8 kHz) in at least one ear
  2. G2Adult: Hearing loss not requiring hearing aid; intervention not indicated; limiting instrumental ADL; threshold shift of >25 dB averaged at 2 contiguous test frequencies in at least one ear (on a 1, 2, 3, 4, 6, and 8 kHz audiogram); Pediatric (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift >20 dB at 4 kHz in at least one ear; mild/moderate impact on age-appropriate normal daily activity
  3. G3Adult: Hearing loss requiring hearing aid; intervention indicated; limiting self-care ADL; threshold shift of >25 dB averaged at 3 contiguous test frequencies in at least one ear(on a 1, 2, 3, 4, 6, and 8 kHz audiogram); Pediatric (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Hearing loss sufficient to indicate therapeutic intervention, including hearing aids; threshold shift >20 dB at 2 to <4 kHz in at least one ear; severe impact on age-appropriate normal daily activity
  4. G4Adult: Nonservicable hearing; decrease in hearing to profound bilateral loss (absolute threshold >80 dB HL at 2 kHz and above); Pediatric: Audiologic indication for cochlear implant; >40 dB HL (i.e., 45 dB HL or more); SNHL at 2 kHz and above
  5. G5Not applicable
Definition and note

DefinitionA disorder characterized by partial or complete loss of the ability to detect or understand sounds resulting from damage to ear structures.

MedDRA code (LLT): 10019245 · CTCAE v6.0 (NCI), original English text.

Other events in Ear and labyrinth disorders

Search another event

From the same authorCódigo OncoCódigo Onco (in Portuguese): Brazilian public health system (SUS) codes for systemic cancer treatment.